News

The antibody is indicated to treat R/R FL patients who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that targets

The regulatory approval has been granted for the therapy to treat moderate-to-severe atopic dermatitis in children whose disease is not controlled with topical prescription therapies or when they

The approval will increase MMR vaccine choices in the US. Priorix (Measles, Mumps and Rubella Vaccine, Live) can be given as two doses. It can also be administered

According to a company statement, sugemalimab was approved for use on unresectable stage III NSCLC patients without disease progression after concurrent or sequential platinum-based chemoradiotherapy. NMPA approved sugemalimab

OrbiMed and Maruho have jointly led the financing round, which has also seen participation from HBM Healthcare Investments, Access Biotechnology, TCG X, Omega Funds, Decheng Capital, Samsara BioCapital,

PreHevbri is said to be the only approved 3-antigen hepatitis B vaccine for adults in the UK. It comprises the three hepatitis B surface antigens, S, pre-S1, and

The new investigational recombinant factor VIII (FVIII) therapy efanesoctocog alfa has been designed to extend protection from bleeds with once-weekly prophylactic dosing for haemophilia A patients. It is

New investor NexPoint led the financing round, which included participation from existing investors Eshelman Ventures, Bristol Myers Squibb, and Kingdon Capital. A convertible note, which was provided by

The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for